Company news

Apellis Pharmaceuticals, Inc. news in 2021

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH

December 14, 2021

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

December 14, 2021

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

December 12, 2021

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 28, 2021

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

November 11, 2021

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

November 9, 2021

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 7, 2021

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting

November 3, 2021

Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results

October 31, 2021

Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH

October 14, 2021

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH

October 14, 2021

Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting

September 29, 2021

Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 19, 2021

Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

September 8, 2021

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer

September 2, 2021

Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 8, 2021

Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results

July 28, 2021

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

July 25, 2021

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

July 6, 2021

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

June 29, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

June 22, 2021

Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH

May 24, 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 13, 2021

Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results

April 27, 2021

Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy

April 12, 2021

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

March 9, 2021

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

January 25, 2021

Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

January 6, 2021

Calls in 2021